Free Trial!
Today’s Best Stocks To Trade! Click Here
Corgenix Medical Corporation (OTCBB: CONX); HepaLife Technologies, Inc. (OTCBB: HPLF); Global Capacity, Inc. (OTCBB: CGSY); Baywood International, Inc. (OTCBB: BYWD); Tikcro Technologies Ltd. (OTC BB: TIKRF); Nutra Pharma Corp. (OTCBB: NPHC)
FinancialBusinessNews is an affiliate of Stock Profiler.US, LLC. To receive your FREE subscription to our newsletter, please visit http://www.stockprofiler.us.
StockProfiler.US, LLC - StockProfiler announces the Launching of its new website (http://www.stockprofiler.us), which offers investors tools and information useful in due diligence for investment decisions. StockProfiler's goal for the new website format is to provide investors and stockbrokers with timely financial news, data and links to valuable investment tools (i.e., stock quotes, stock charts, stock research, stock message boards, etc.) that will enable them to make more informed investment decisions.
Sign up Today for Your Free Stock and Updated News Subscription at http://www.stockprofiler.us Companies who want to broadcast their progress are welcome to contact Stockprofiler.US, LLC at 603-621-9420.
-------------------------------------------
Corgenix Medical Corporation (OTCBB: CONX)
Corgenix Medical Corporation closed at $0.32 Friday, trading 46,350 shares.
For current trading information on Corgenix Medical Corporation including continually updating stock quotes, interactive charts, news, research and Nasdaq Level 2 data, go to http//www.StockProfiler.US
Company News- December 17, 2007: Corgenix Signs Cooperative Research and Development Agreement With National Institutes of Health (NIH)
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced earlier today that it has entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
The two-year study will use the Corgenix Hyaluronic Acid (HA) test kit alone and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in nonalcoholic steatohepatitis (NASH) patients. NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-NIDDK study is focused on developing a non-invasive method of diagnosis.
Nonalcoholic fatty liver disease (NAFLD) is a chronic, typically mild liver condition associated with obesity and insulin resistance, characterized by the presence of fat in the liver. Currently recognized as the most common cause of chronic liver disease in the U.S., NAFLD affects 20-24 percent of Americans. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD associated with inflammation and damage to the liver that can progress to fibrosis and cirrhosis. Approximately 2-5 percent of the U.S. population has NASH.
Since NASH carries a high risk of portal hypertension, liver failure requiring liver transplantation, and hepatocellular carcinoma, it is important to identify these individuals for prognostic and patient management decisions. Currently, the only reliable way to distinguish between NAFLD and NASH is by liver biopsy, which is costly (especially when considering that 60 - 75 million individuals in the U.S. have NAFLD), painful and carries some risk to patients. The aim of this study is to identify non-invasive, reliable markers to identify patients at risk for NASH.
"We are very excited about our collaboration with the NIH. This is a definitive study that will apply our HA product to a very important and clearly under-diagnosed condition that affects a significant percentage of the U.S. population," said Corgenix President and Chief Executive Officer Douglass Simpson. "With the rate of obesity in the U.S. continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, non-invasive methods for assessment." "Nonalcoholic steatohepatitis is a major healthcare problem. It is typically a silent' disease with few or no symptoms until the disease is advanced," said Luis Lopez, M.D., Corgenix Chief Medical Officer. "NASH patients whose disease has progressed to cirrhosis have a 7-10 year mortality of up to 25 percent. We believe this study has the potential to make a major difference in literally millions of individuals when completed." The Corgenix Hyaluronic Acid test kit has not been cleared by the U.S. Food and Drug Administration for in vitro diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, the products shall not be used for diagnostic use as the performance characteristics have not been established. The Hyaluronic Acid test kit is CE-marked for sale in the European Union.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global
-------------------------------------------
HepaLife Technologies, Inc. (OTCBB: HPLF)
HepaLife Technologies, Inc. closed at $0.50 Friday, trading 87,377 shares.
For current trading information on HepaLife Technologies, Inc. including continually updating stock quotes, interactive charts, news, research and Nasdaq Level 2 data, go to http//www.StockProfiler.US
Company News- December 17, 2007: HepaLife Surpasses Significant Milestones in Development of Artificial Liver Device
HepaLife Technologies, Inc. (OTCBB: HPLF | charts | news | PowerRating) (FWB: HL1) (WKN: 500625) is pleased to have announce details of a series of significant achievements in the development of the first-of-its-kind bioartificial liver device, allowing the Company to move closer to initial in-vivo trials.
Key to the success of the Company's artificial liver device are HepaLife's patented PICM-19 embryonic liver stem cells, which scientists have demonstrated possess a number of unique characteristics, making their liver-specific metabolic functionality superior to other cells, including the world's most widely used human liver cell line.
The unique functionality of the PICM-19 cells allow them to successfully mimic the human liver's response in several important ways, including their ability to express high levels of cytochrome P-450 enzymes, a key liver-related function in the detoxification of drugs and xenobiotics, and to favorably produce urea and successfully remove ammonia, a highly toxic by-product which causes brain damage, coma, and even death.
"Not only is HepaLife's PICM-19 cell line the only known embryonic liver stem cell line of its kind with the ability to produce substantial amount of urea, but it also uniquely differentiates into hepatocytes (liver cells) or bile duct epithelium," states Mr. Frank Menzler, President and CEO of HepaLife Technologies, Inc.
"Now, with the integration of the PICM-19 cell into our proprietary bioreactor and perfusion system, the concept of the HepaLife bioartificial liver is nearly complete. This year has been remarkable and we continue to overachieve on our goals, both from a corporate and scientific perspective, moving us closer to initial in-vivo trials." HepaLife's BioArtificial Liver One of the main functions of the human liver is the detoxification of ammonia, which is primarily done through the synthesis of urea. Patients with acute liver failure or genetic liver diseases are often unable to remove ammonia from the bloodstream, leading to brain damage, coma, and death.
In previous tests, HepaLife's PICM-19 cells were able to successfully synthesize 100% of the ammonia present, almost four times more than HepG2-C3A, currently the world's most widely-used human liver cell line. Most significantly, a large proportion of the ammonia was specifically synthesized into urea by the PICM-19 cells. In comparison, HepG2-C3A synthesized none of the ammonia into urea. Notably, HepaLife's PICM-19 cell line is the only known embryonic liver stem cell line of its kind with the ability to produce substantial amounts of urea in an in-vitro system.
Results also demonstrated that the PICM-19 cells are able to express high levels of cytochrome P-450 enzymes, a key liver related function in the detoxification of drugs and xenobiotics. In contrast, HepG2-C3A showed very low, or no detectable P-450 activity at all.
Incorporating the PICM-19 cell line, HepaLife is developing the first-of-its-kind bioartificial liver. HepaLife's bioartificial liver, currently under development, is designed to operate outside the patient's body. The bioartificial liver is envisioned to mimic important functions of the human liver by circulating the patient's blood inside the device, where it is exposed to HepaLife's patented PICM-19 liver stem cells, thus processing the patient's blood-plasma by removing toxins, enhancing metabolic function, and ultimately imitating the liver's natural function.
Intended for the treatment of liver failure, the HepaLife bioartificial liver device consists of three basic components: (1) a plasma filter, separating the patients blood into blood plasma and blood cells; (2) the bioreactor, a unit filled with PICM-19 cells which biologically mimic the liver's function; and (3), the HepaDrive, a perfusion system for pumping the patient's plasma through the bioreactor while controlling gas supply and temperature for best possible performance of the cells.
Long running in-vitro tests of the HepaLife bioartificial liver showed that the system removed toxic ammonia, and successfully produced significant amounts urea and liver specific protein, such as albumin, over the entire duration of the study. Most importantly, the production of urea and albumin increased over time, reaching peak levels at termination of the two week study.
In observations of cell replication and growth, researchers confirmed earlier findings where PICM-19 liver cells remained contact-inhibited, an important indicator of normal cell growth, since cells which lack contact-inhibition tend to become cancerous. In contrast to cells which are not contact-inhibited, HepaLife's PICM-19 cells did not develop tumors nor become cancerous inside the liver device system, instead remaining non-tumorigenic.
In the same tests, HepaLife's PICM-19 liver stem cells successfully differentiated into hepatocytes (liver cells) displaying normal morphology, an indication of the cells' natural physical form and structure.
In evaluating the chemical function and overall health of the PICM-19 liver cells inside HepaLife's bioartificial liver, researchers analyzed levels of lactate and glucose -- indicators of metabolic function -- alongside oxygen and carbon dioxide. In all cases, these monitored levels remained favorably within targeted parameters throughout the duration of the studies.
"The combination of the superior metabolic performance of our PICM-19 cell line along with our new bioreactor and perfusion system truly sets us apart from anyone else. Each new step we take along the development pathway brings us that much closer to creating the world's first-of-its-kind bioartificial liver device," concludes Mr. Menzler.
ABOUT HEPALIFE TECHNOLOGIES, INC.
HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) is a developer of cell-based medical technologies addressing prevalent human health concerns.
Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses.
-------------------------------------------
Global Capacity, Inc. (OTCBB: CGSY)
Global Capacity, Inc. closed at $0.65 Friday, trading 45,900 shares.
For current trading information on Global Capacity, Inc. including continually updating stock quotes, interactive charts, news, research and Nasdaq Level 2 data, go to http//www.StockProfiler.US
Company News- December 17, 2007: Global Capacity Awarded More Than $4.4 Million in New Customer Contracts
Global Capacity, Inc. (parent: Capital Growth Systems, Inc. (OTCBB: CGSY)), announced earlier today that it has won 7 new network management and professional services contracts with government, health care, enterprise, service provider and higher education customers, further validating the Company's telecom logistics business model. Customers include a large city government, a university health care system, a major supermarket chain, a Fortune 500 manufacturing firm, a financial services firm, an international telecommunications carrier, and a state university. Total value of these new contracts exceeds $4.4 million.
"More and more companies are placing their trust in Global Capacity to help navigate the complex telecom supply chain for network solutions," said Patrick Shutt, CEO of Global Capacity. "Companies across multiple segments and geographies recognize the value of our fully integrated telecom logistics model, and we remain committed to helping them improve efficiency, reduce cost and simplify the operations of their critical network infrastructures. The trust and support of our customers is critical as we pursue our growth objectives, and we are pleased that these new contracts are further proof of that trust and support."
About Global Capacity
Global Capacity is the operating arm of Capital Growth Systems, Inc. (OTCBB: CGSY). The telecom logistics company provides a fully integrated supply chain management system that streamlines and accelerates the process of designing, building and managing customized communications networks. It offers a comprehensive suite of services to enterprises, systems integrators and carrier customers worldwide. Global Capacity has operational centers in Waltham, MA; Manchester, England and Houston, TX; with offices in Chicago, IL; New York, NY; and Lisbon, Portugal. For more information, please visit www.globalcapacity.com or contact 866.226.4244.
-------------------------------------------
Baywood International, Inc. (OTCBB: BYWD)
Baywood International, Inc. closed at $0.0312 Friday, trading 0 shares.
For current trading information on Baywood International, Inc. including continually updating stock quotes, interactive charts, news, research and Nasdaq Level 2 data, go to http//www.StockProfiler.US
Company News- December 17, 2007: New Research on Resveratrol Reveals Benefit in Curbing Insulin Resistance
Baywood International, Inc. (OTCBB: BYWD | charts | news | PowerRating) ("Company") announced earlier today that resveratrol, an antioxidant found in red wine, may counter type 2 diabetes and insulin resistance, according to a new study.
Insulin is a hormone that controls blood sugar. Insulin resistance occurs when the body becomes less sensitive to insulin. This condition can lead to type 2 diabetes. Chinese scientists report that resveratrol curbs insulin resistance in mice. These scientists, including Cheng Sun and Qiwei Zhai of the Chinese Academy of Sciences in Shanghai, indicate that this is a "valuable new strategy for treating insulin resistance and type 2 diabetes." If the findings apply to people, it might be possible to create new resveratrol compounds. However, to reach the same levels of resveratrol, it would require a significant consumption of red wine.
"According to [our] findings, people might need to drink about three liters of red wine each day to get sufficient resveratrol - about 15 milligrams - for its biological effects," Zhai said in a news release, although the researchers did not recommend that anyone rely on wine to help their insulin sensitivity.
Resveratrol is found in grapes (especially in red wine), raspberries, peanuts, and other plants that use resveratrol to defend against threats such as disease. Sun's team found that insulin-resistant mice become more sensitive to insulin when given resveratrol. The scientists' experiments with cells in test tubes show that resveratrol spurs a gene called SIRT1 to become more active, boosting insulin sensitivity.
According to the American Diabetes Association, (www.diabetes.org), there are 20.8 million children and adults in the United States, or 7% of the population, who have diabetes. While an estimated 14.6 million have been diagnosed, unfortunately, 6.2 million people (or nearly one-third) are unaware that they have the disease and 54 million people are estimated to be pre-diabetic. About 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in 2005.
The total annual economic cost of diabetes in 2002 (latest year for which data is available) was estimated to be $132 billion. Direct medical expenditures totaled $92 billion and comprised $23.2 billion for diabetes care, $24.6 billion for chronic diabetes-related complications, and $44.1 billion for excess prevalence of general medical conditions. Indirect costs resulting from lost workdays, restricted activity days, mortality, and permanent disability due to diabetes totaled $40.8 billion. Furthermore, one out of every 10 health care dollars spent in the United States is spent on diabetes and its complications.
During the third quarter of this year, the Company's wholly-owned subsidiary, Nutritional Specialties, Inc./dba LifeTime , launched Resveratrol Life Tonic in liquid form for enhanced bioavailability. The product's powerful antioxidant properties include 300 mg of resveratrol extract in each one ounce serving, which is equivalent to 1,300 glasses of red wine. For more information, visit www.lifetimevitamins.com/products/lifetime_resveratrol.html.
About Baywood:
Baywood International, Inc. (OTC BB: BYWD | charts | news | PowerRating) is a nutraceutical company specializing in the development, marketing and distribution of its own proprietary brands under the names Baywood PURECHOICE , Baywood SOLUTIONS and Complete La Femme . The Company's products are distributed through independent and chain health food stores, pharmacies, grocery stores, and other direct-to-consumer channels both internationally and domestically. Baywood's wholly-owned subsidiary, Nutritional Specialties, Inc./dba LifeTime or LifeTime Vitamins ("LifeTime"), is a nutraceutical company that was established in 1988 and specializes in the development, marketing and distribution of its own brands under the LifeTime name. LifeTime's brands currently consist of approximately 370 products that are sold directly to independent and chain health food stores, pharmacies, natural food stores, and other direct-to-consumer channels across the United States. In addition, LifeTime's products are sold internationally through distributors in Canada, Croatia, Turkey, England, Dubai, Holland, Sweden, Portugal and certain parts of Asia. For more information, call (888) 350-0799, or for more information, visit www.bywd.com.
-------------------------------------------
Nutra Pharma Corp. (OTCBB: NPHC)
Nutra Pharma Corp. closed at $0.026 Friday, trading 126,446 shares.
For current trading information on Nutra Pharma Corp. including continually updating stock quotes, interactive charts, news, research and Nasdaq Level 2 data, go to http//www.StockProfiler.US
Company News- December 17, 2007: Nutra Pharma Announces Successful Completion of 6-Month Patient Crossover in AMN Clinical Trial
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), announced earlier today that its drug discovery arm, ReceptoPharm, has successfully completed its six-month patient crossover in the Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN).
The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo. RPI-78M is ReceptoPharm's lead drug candidate for the treatment of neurological and autoimmune disorders.
"This is an important milestone in our clinical development process, as successful completion of this crossover acts as an early indication that our trial is running smoothly," explained Paul Reid, CEO of ReceptoPharm, Inc. "As we move into the second-half of our trial, we will continue to monitor patients closely to determine efficacy of our treatment," he added.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades. AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease's rarity designates it as an orphan drug candidate both in Europe and in the U.S. The Company has applied for Orphan drug status in the U.S. and intends doing so for the EU.
"We're confident in what we've seen in previous patient trials. But because this is a double-blind, placebo-controlled study, we will not know patient results until the trial is fully-completed," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As the study progresses, we will continue to provide relevant information about this trial to our shareholders and to the public," he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. FinancialBusinessNews.US has not been compensated for services rendered; FinancialBusinessNews.US is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.financialbusinessnews.us/ (disclaimers).
CONTACT: FinancialBusinessNews.US e-mail: info@http://www.financialbusinessnews.us WWW: http://www.financialbusinessnews.us/
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
